Condition: Juvenile Psoriatic Arthritis · Sponsor: AbbVie
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. PsA that begins before a patient's 16th birthday is called juvenile PsA (jPsA).This study will evaluate how safe risankizumab is for the treatment of psoriatic arthritis and to assess change in disease symptoms. Risankizumab is being studied for the treatment of jPsA and adalimumab is approved for the treatment of jPsA. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to receive adalimumab. Approximately 40 juvenile participants with jPsA will be enrolled at approximately 30 sites worldwide. Participants will receive risankizumab and adalimumab as subcutaneous (SC) injections based on body weight. At the start of Period 1, participants are randomized to receive risankizumab or adalimumab for 24 weeks. Participants who respond to the study treatment received in Period 1, will continue to receive the same treatment in Period 2 for another 100 weeks. Those with worsening jPsA symptoms in Period 2 will be withdrawn from the study. Participants who receive adalimumab are followed for safety for 70 days after the last study treatment. Participants who receive risankizumab are followed for 140 days after the last study treatment. There may …
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Arkansas Children's Hospital /ID# 258776 | Little Rock, Arkansas, United States | Recruiting |
| Childrens National Medical Center /ID# 259284 | Washington D.C., District of Columbia, United States | Recruiting |
| Joe Dimaggio Children's Hospital Hollywood /ID# 260634 | Hollywood, Florida, United States | Recruiting |
| All X Ray Diagnostic Services Corp /ID# 278523 | Miami, Florida, United States | Recruiting |
| Indiana University Health Riley Hospital for Children /ID# 259067 | Indianapolis, Indiana, United States | Recruiting |
| M Health Fairview University of Minnesota Medical Center - West Bank /ID# 260111 | Minneapolis, Minnesota, United States | Recruiting |
| Columbia University Medical Center /ID# 262587 | New York, New York, United States | Recruiting |
| Boston Childrens Health Physicians /ID# 258061 | Valhalla, New York, United States | Recruiting |
| University of North Carolina - Children's Hospital /ID# 259286 | Chapel Hill, North Carolina, United States | Recruiting |
| MetroHealth Medical Center /ID# 262377 | Cleveland, Ohio, United States | Recruiting |
| Child Neurology Consultants of Austin /ID# 260562 | Austin, Texas, United States | Recruiting |
| Monash Health - Monash Medical Centre - Clayton /ID# 260255 | Clayton, Victoria, Australia | Recruiting |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06100744